Today: 1 July 2026
AppLovin stock slides into 2026 as investors test its sky-high margins
2 January 2026
2 mins read

AppLovin stock slides into 2026 as investors test its sky-high margins

NEW YORK, January 2, 2026, 10:38 ET

  • AppLovin shares fell about 6% in morning trade as a year-end pullback deepened.
  • Zacks notes flagged an outsized “revenue-to-profit” conversion in the latest reported quarter, with an 82% adjusted EBITDA margin.
  • Investors are watching whether growth and cash generation can justify a premium valuation versus ad-tech peers.

AppLovin shares fell about 6% on Friday morning, extending a retreat that began in the final days of 2025 as investors reassessed one of the market’s standout momentum names.

The move matters at the start of the year because AppLovin’s run-up has made the stock unusually sensitive to valuation questions and any hint that growth is cooling, even without new company-specific news.

Wall Street’s focus is narrowing to the next earnings release, with analysts looking for another step-up in profit while revenue growth moderates from last year’s pace.

In the latest closing session on Dec. 31, AppLovin ended down 2.87% at $673.82, lagging a broad market decline, according to a Zacks Equity Research note.

A separate Zacks note highlighted what it called AppLovin’s unusually strong conversion of incremental revenue into profit and cash, pointing to the company’s third-quarter 2025 results: revenue of $1.41 billion, up 68% year over year; adjusted EBITDA of $1.16 billion, up 79% for an 82% margin; and free cash flow of $1.05 billion, up 92%.

Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization, excluding certain items, and is often used as a rough gauge of operating profitability. Free cash flow measures cash left after operating costs and capital spending.

Zacks attributed the margin profile to what it called a “MAX–AXON flywheel,” where AppLovin’s MAX software helps app developers auction ad space in real time, feeding data back into AXON, the company’s ad-targeting engine. Zacks said early traction in a self-serve AXON Ads Manager could reinforce that loop without heavy sales costs.

A separate deep-dive by PredictStreet described AppLovin as increasingly centered on software for mobile advertising and measurement, arguing that AI-driven optimization has helped it adapt to tougher privacy rules on smartphones.

Competitive comparisons are also sharpening. Zacks said Unity Software remains closely tied to mobile gaming monetization but has struggled with margin stability, while The Trade Desk’s business model still reflects higher reinvestment needs, making AppLovin’s profit “flow-through” stand out.

Valuation remains the counterweight. In its Dec. 31 note on the stock’s daily move, Zacks said AppLovin was trading at a premium on a forward price-to-earnings basis and cited a PEG ratio — a P/E measure adjusted for expected growth — that was above the industry average.

On earnings, Zacks said AppLovin is expected to post quarterly earnings per share of $2.89, up about 67% from a year earlier, on revenue of roughly $1.6 billion. For the full year, Zacks’ consensus called for earnings of $9.32 per share and revenue of $5.57 billion.

AppLovin has been repositioning for that mix of growth and cash generation since exiting game development. “The closing of this transaction streamlines the Company to its core business,” CEO Adam Foroughi said in a July 2025 statement announcing the completed sale of its mobile gaming business to Tripledot Studios. Applovin

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Kymera Therapeutics (KYMR) up 51% YTD as atopic dermatitis drug hits milestones
    July 1, 2026, 2:57 PM EDT. Kymera Therapeutics (KYMR) is up nearly 51% this year, way ahead of the sector's 6.4%. The stock's gain is tied to progress on KT-621, an oral STAT6 degrader for atopic dermatitis and asthma. Kymera wrapped phase IIb enrollment in the BROADEN2 AD trial six months early, aiming to have the pivotal readout by late 2026. Earlier, phase Ib data showed strong STAT6 knockdown and safety. The FDA put KT-621 on Fast Track for moderate-to-severe AD and eosinophilic asthma. Separately, trials for KT-485, in partnership with Sanofi, led to a $20 million milestone, and Kymera is still developing KT-579. Its alliances with Sanofi and Gilead are part of the company's long-term plans.
Chevron stock today: CVX steadies near $152 as oil logs steepest annual drop since 2020
Previous Story

Chevron stock today: CVX steadies near $152 as oil logs steepest annual drop since 2020

Hyperscale Data (GPUS) stock jumps 20% in premarket as insider buying keeps spotlight on the microcap
Next Story

Hyperscale Data (GPUS) stock jumps 20% in premarket as insider buying keeps spotlight on the microcap

Go toTop